Larry Schlabach, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
Wright State University Boonshoft
Medical School
Erlanger Medical Center
Residency
University of Alabama Medical Center
Fellowship
American Board of Internal Medicine - Oncology
GA State Medical License: 1995 - 2017
TN State Medical License: 1988 - 2017
American Board of Internal Medicine: Medical Oncology
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin, D. B.,Goff, L.,Li, C. I.,Shyr, Y.,Winkler, C.,Devore, R.,Schlabach, L.,Holloway, M.,McClanahan, P.,Meyer, K.,Grigorieva, J.,Berlin, J.,Chan, E.; Cancer Med. 2014 Feb 28.
See more >>A phase II study of concurrent chemoradiotherapy with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and ca...
Hughes RS, Sandler AB, Jain AK, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H; J. Clin. Oncol.. 2008-05-20.
See more >>57 citations Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Heymach, J. V., Johnson, D. H., Khuri, F. R., Safran, H., Schlabach, L. L., Yunus, F., DeVore, R. F., De Porre, P. M., Richards, H. M., Jia, X., Zhang, S., Johnson, B. E.; Ann Oncol. 2004 Aug.
See more >>American College of Physicians